PEAK6 Investments LLC Sells 2,500 Shares of Twist Bioscience Co. (NASDAQ:TWST)

PEAK6 Investments LLC cut its position in Twist Bioscience Co. (NASDAQ:TWST) by 14.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,000 shares of the company’s stock after selling 2,500 shares during the quarter. PEAK6 Investments LLC’s holdings in Twist Bioscience were worth $678,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Signaturefd LLC increased its stake in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the period. EdgeRock Capital LLC bought a new stake in Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. increased its position in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience during the second quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 1,730 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the transaction, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Paula Green sold 1,057 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the completion of the transaction, the senior vice president now owns 121,013 shares in the company, valued at approximately $5,029,300.28. This represents a 0.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock valued at $4,391,151 over the last ninety days. 3.92% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

TWST has been the subject of several analyst reports. Scotiabank raised their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. TD Cowen restated a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Barclays lowered their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, Leerink Partners upped their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $51.00.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $50.61 on Wednesday. The stock’s 50 day moving average price is $44.02 and its two-hundred day moving average price is $46.27. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -14.06 and a beta of 1.82. Twist Bioscience Co. has a 52-week low of $24.15 and a 52-week high of $60.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.